← Back to Search

Glycopeptide Antibiotic

Dalbavancin for Osteomyelitis

Phase 4
Waitlist Available
Led By Donald Poretz, MD
Research Sponsored by Infectious Diseases Physicians, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluated at day 365
Awards & highlights

Study Summary

This trial is testing whether the antibiotic dalbavancin can be used to treat Gram-positive infections caused by bacteria including MRSA and streptococcal species. The hope is that dalbavancin can reduce the length of treatment and related costs and morbidity.

Eligible Conditions
  • Prosthetic Joint Infections
  • Osteomyelitis
  • Joint Infections
  • Septic Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluated at day 365
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluated at day 365 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical response (non-failure) to assigned treatment at day #42
Secondary outcome measures
CRP Improvement at day #180
CRP Improvement at day #365
CRP Improvement at day #90
+3 more

Side effects data

From 2018 Phase 4 trial • 91 Patients • NCT03233438
2%
Hypoglycaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Usual Care
New Critical Pathway

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DalbavancinExperimental Treatment1 Intervention
Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
Group II: Standard of CareActive Control1 Intervention
Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dalbavancin
FDA approved

Find a Location

Who is running the clinical trial?

Infectious Diseases Physicians, Inc.Lead Sponsor
Johns Hopkins UniversityOTHER
2,259 Previous Clinical Trials
14,820,612 Total Patients Enrolled
Donald Poretz, MDPrincipal InvestigatorInfectious Diseases Physicians, Inc.
1 Previous Clinical Trials
6 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
2018. "Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03426761.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top